Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects (NSERC partnered)

University of Toronto

$273,483.00

Degradable Cardiac Patch with Immuno-modulatory function

EF 2016-17

Résumé
Cardiovascular disease (CVD) is the leading cause of death in the world. Specifically, in 2012, CVD was responsible for ~17.5 million deaths globally and 62,000 deaths in Canada, costing the Canadian economy more than $21.2 billion. Myocardial infarction or heart attacks represent the main cause of CVD-related deaths, resulting in irreversible heart muscle damage due to the limited regenerative capacity of the heart. This can ultimately lead to end-stage heart failure, which is currently treated using heart transplantation and ventricular assist devices (VADs). However, a shortage of donor organs as well as the high cost of VADs and their lack of long-term suitability for all patient types are significant limitations of these standard treatments. Tissue engineering and the development of cardiac tissue has become a promising method for the repair and replacement of damaged myocardium and a means of preventing end-stage heart failure. In this project, and utilizing the biomaterial expertise of Santerre lab and the cardiovascular biology expertise of the Bendeck lab (both at the University of Toronto) and clinical expertise of the Dr. Epelman lab at the University Hospital network, a novel degradable polyurethane scaffold, using a biomaterial platform that has been shown to modulate the early immune response upon implantation, will be combined with cardiac cells, which will be derived from adipose stem cells, in order to develop a functional and vascularized cardiac patch. The properties, performance and survival of the resulting engineered patch will studied for their in vivo benefit.
Programme
Collaborative Health Research Projects (NSERC partnered)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
361210
Name
Santerre Paul
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Natural Sciences and Engineering Research Council of Canada (NSERC)
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Collaborative Health Research Projects - NSERC Partnered
Projecttitle
Degradable Cardiac Patch with Immuno-modulatory function
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$273,483
Cihrequipment2
$0
Programname2
Collaborative Health Research Projects (NSERC partnered)
Keyworddelim
Angiogenesis; Biomaterials; Cardiac Tissue; Cardiomyocytes; Drug Delivery; Fibroblasts; Growth Factors; Heart Physiology; Nanoparticles; Tissue Engineering
Abstract
Cardiovascular disease (CVD) is the leading cause of death in the world. Specifically, in 2012, CVD was responsible for ~17.5 million deaths globally and 62,000 deaths in Canada, costing the Canadian economy more than $21.2 billion. Myocardial infarction or heart attacks represent the main cause of CVD-related deaths, resulting in irreversible heart muscle damage due to the limited regenerative capacity of the heart. This can ultimately lead to end-stage heart failure, which is currently treated using heart transplantation and ventricular assist devices (VADs). However, a shortage of donor organs as well as the high cost of VADs and their lack of long-term suitability for all patient types are significant limitations of these standard treatments. Tissue engineering and the development of cardiac tissue has become a promising method for the repair and replacement of damaged myocardium and a means of preventing end-stage heart failure. In this project, and utilizing the biomaterial expertise of Santerre lab and the cardiovascular biology expertise of the Bendeck lab (both at the University of Toronto) and clinical expertise of the Dr. Epelman lab at the University Hospital network, a novel degradable polyurethane scaffold, using a biomaterial platform that has been shown to modulate the early immune response upon implantation, will be combined with cardiac cells, which will be derived from adipose stem cells, in order to develop a functional and vascularized cardiac patch. The properties, performance and survival of the resulting engineered patch will studied for their in vivo benefit.
Competitiondate
201610
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Santerre, Paul; Bendeck, Michelle P
Approvedterm
3 ans 0 mois
Cihrcontribution2
Major Initiatives #2~ $273,483~ $0~